The previously named “IDH—mutant secondary glioblastoma” has been reclassified as IDH—mutant Grade 4 astrocytoma, which has a survival rate at least two-fold higher than IDH—wildtype glioblastoma. This evidence concerns the gene IDH1 and glioblastoma.